BlueCross BlueShield
Federal Employee Program
Blue Cross Blue Shield Association
750 9th St NW, Suite 900
Washington, D.C. 20001
1-800-624-5060
Fax 1-877-378-4727

5.21.250

Section:	Prescription Drugs	**Effective Date:**	April 1, 2026
Subsection:	Antineoplastic Agents	**Original Policy Date:**	October 24, 2025
Subject:	Inluriyo	**Page:**	1 of 4

Last Review Date: March 6, 2026

Inluriyo

Description

Inluriyo (imlunestrant)

Background
Inluriyo (imlunestrant) is an estrogen receptor (ER) antagonist that binds to the estrogen receptor-alpha (ERα). In vitro, Inluriyo induced degradation of ERα, leading to inhibition of ER-dependent gene transcription and cellular proliferation in ER+ breast cancer cells. Inluriyo demonstrated in vitro and in vivo anti-tumor activity in ER+ breast cancer xenograft models, including models with estrogen receptor 1 gene (*ESR1)* mutations (1).

Regulatory Status
FDA-approved indication: Inluriyo is an estrogen receptor antagonist indicated for: (1)

- Treatment of adults with ER-positive, HER2-negative, *ESR1*-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy.

The recommended dosage of Inluriyo is 400 mg once daily. Patients should avoid taking Inluriyo with strong CYP3A inhibitors and inducers. If concomitant use with strong CYP3A inhibitors cannot be avoided, decrease Inluriyo dosage to 200 mg once daily. If concomitant use with strong CYP3A inducers cannot be avoided, increase the Inluriyo dosage to 600 mg once daily (1).

Inluriyo can cause fetal harm when administered to a pregnant woman. Females of reproductive potential should be advised to use effective contraception during treatment with Inluriyo and for 1 week after the last dose. Male patients with female partners of reproductive potential should be advised to use effective contraception during treatment with Inluriyo and for 1 week after the last dose (1).

The safety and effectiveness of Inluriyo in pediatric patients less than 18 years of age have not been established (1).

Related policies
Orserdu

Policy

This policy statement applies to clinical review performed for pre-service (Prior Approval, Precertification, Advanced Benefit Determination, etc.) and/or post-service claims.

Inluriyo may be considered **medically necessary** if the conditions indicated below are met.

Inluriyo may be considered **investigational** for all other indications.

Prior-Approval Requirements

Age 18 years of age or older

Diagnosis

Patient must have the following:

1. Advanced or metastatic breast cancer
    a. ER-positive, HER2-negative
    b. Presence of *ESR1* mutation in plasma specimen using an FDA-approved test
    c. Patient has had disease progression following at least one line of endocrine therapy

AND ALL of the following:

a. Females of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Inluriyo and for 1 week after the last dose
b. Males with female partners of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Inluriyo and for 1 week after the last dose

---

Prior – Approval *Renewal* Requirements

Age 18 years of age or older

Diagnosis

Patient must have the following:

1. Advanced or metastatic breast cancer
    a. ER-positive, HER2-negative
    b. Presence of *ESR1* mutation in plasma specimen using an FDA-approved test

AND ALL of the following:
a. **NO** disease progression or unacceptable toxicity
b. Females of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Inluriyo and for 1 week after the last dose
c. Males with female partners of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Inluriyo and for 1 week after the last dose

Policy Guidelines

Pre - PA Allowance

None

Prior - Approval Limits

Quantity 600 mg daily

Duration 12 months

Prior – Approval *Renewal* Limits

Same as above

Rationale

Summary

Inluriyo (imlunestrant) is an estrogen receptor antagonist indicated for the treatment of ER-positive, HER2-negative, *ESR1*-mutated advanced or metastatic breast cancer. Inluriyo contains a warning regarding embryo-fetal toxicity. The safety and effectiveness of Inluriyo in pediatric patients less than 18 years of age have not been established (1).

Prior approval is required to ensure the safe, clinically appropriate, and cost-effective use of Inluriyo while maintaining optimal therapeutic outcomes.

References

1. Inluriyo [package insert]. Indianapolis, IN: Eli Lilly and Company; September 2025.
2. NCCN Drugs & Biologics Compendium® Imlunestrant 2026. National Comprehensive Cancer Network, Inc. Accessed on February 2, 2026.

Policy History

Date	Action
October 2025	Addition to PA
March 2026	Annual review and reference update

Keywords

This policy was approved by the FEP® Pharmacy and Medical Policy Committee on March 6, 2026 and is effective on April 1, 2026.